Avantor (AVTR) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
15 Oct, 2026Executive summary
Q4 and FY 2023 revenue, adjusted EBITDA and adjusted EPS finished at the high end of updated guidance; FY free cash flow exceeded the top end of guidance.
Market conditions remained stable, with destocking and cautious spending weighing on demand; customer signals and leading indicators were encouraging, but no end-market inflection had emerged.
Financial highlights
Q4 revenue was $1,722.8M, down 4.0%; FY revenue was $6,967.2M, down 7.3%. Core organic growth was -4.8% in Q4 and -5.2% for FY; FX added 1.9% and 0.5%, respectively.
Q4 adjusted EBITDA was $302.1M (17.5% margin) and adjusted EPS was $0.25; FY adjusted EBITDA was $1,309.1M (18.8% margin) and adjusted EPS was $1.06.
Q4 net income was $98.5M and adjusted net income $166.7M; FY net income was $321.1M and adjusted net income $720.1M. Diluted GAAP EPS was $0.15 in Q4 and $0.47 for FY.
Adjusted gross profit was $570.4M in Q4 (33.1% margin) and $2,363.8M for FY (33.9% margin).
Free cash flow was $201.0M in Q4 and $723.6M for FY, with conversion above 120% and 100%, respectively.
Outlook and guidance
FY 2024 organic revenue growth guidance is -2% to +1%; reported revenue is $6.85B-$7.06B, implying reported growth of -1.7% to +1.3%.
FY 2024 adjusted EBITDA guidance is $1.19B-$1.26B, with a 17.4%-17.9% margin; adjusted EPS guidance is $0.96-$1.04.
FY 2024 free cash flow guidance is $600M-$650M, excluding one-time cash costs for the operating model transformation and cost-savings initiative.
Guidance assumes current market conditions continue; recovery could provide upside but is not assured. Estimates use a FY blended USD/EUR rate of 1.08.
Latest events from Avantor
- Organic growth, stronger margins, and IPO-funded deleveraging marked 2019.AVTR
Q4 2019 - Biopharma-led growth lifted sales, margins and cash flow despite uneven pandemic impacts.AVTR
Q4 2020 - 11.3% organic growth, 190-bps margin expansion and $4B+ deployed across three acquisitions.AVTR
Q4 2021 - Core growth and margin gains offset FX headwinds as cash funded debt reduction and expansion.AVTR
Q4 2022 - Organic growth returned in both segments as guidance rose and net debt declined.AVTR
Q3 2026 - Q2 2026 delivered higher sales, strong cash flow, and raised guidance amid improved segment results.AVTR
Q2 2026 - All proposals passed, directors elected, and no questions raised during the meeting.AVTR
AGM 2026 - Q2 2025 net sales and margins declined, with guidance cut and a CEO transition announced.AVTR
Q2 2025 - Q4 growth, margin gains, and strong cash flow support continued improvement and deleveraging in 2025.AVTR
Q4 2024